Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. - Mendes D; Averin A; Atwood M; Sato R; Vyse A; Campling J; Weycker D; Slack M; Ellsbury G; Mugwagwa T (Expert review of pharmacoeconomics & outcomes research, 2022)